^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunostimulant

    Related drugs:
    1d
    A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults (clinicaltrials.gov)
    P1, N=96, Recruiting, University Hospital Tuebingen | N=60 --> 96 | Trial completion date: Aug 2028 --> Dec 2026 | Trial primary completion date: Aug 2027 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    2d
    IOV-PED-101: Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Iovance Biotherapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Amtagvi (lifileucel) • LN-145
    2d
    Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer (clinicaltrials.gov)
    P1, N=210, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2033 --> Feb 2029 | Trial primary completion date: Jun 2031 --> Feb 2029
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • SLATE-KRAS
    2d
    CRUKD/20/001: A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov)
    P1/2, N=15, Suspended, Cancer Research UK | Trial completion date: Mar 2029 --> Oct 2026
    Trial completion date • Checkpoint inhibition • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
    |
    VTP-600
    5d
    Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age (clinicaltrials.gov)
    P1/2, N=1407, Active, not recruiting, ModernaTX, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    5d
    Age-descending Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Adults and Children (clinicaltrials.gov)
    P2, N=390, Recruiting, International Vaccine Institute
    New P2 trial
    6d
    BPL-1357 Against H1N1 Influenza Virus Challenge (clinicaltrials.gov)
    P2, N=129, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting --> Recruiting
    Enrollment open
    6d
    RSV Vaccination to Reduce Recurrent AECOPD (clinicaltrials.gov)
    P4, N=320, Not yet recruiting, Chinese University of Hong Kong
    New P4 trial
    6d
    Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma (clinicaltrials.gov)
    P1, N=17, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion • First-in-human
    |
    BRAF (B-raf proto-oncogene) • IL2 (Interleukin 2)
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • TIDAL-01
    6d
    A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above (clinicaltrials.gov)
    P1, N=240, Active, not recruiting, Shenzhen Shenxin Biotechnology Co., Ltd | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IL4 (Interleukin 4)
    7d
    Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (clinicaltrials.gov)
    P3, N=2195, Recruiting, Sanofi | N=896 --> 2195 | Trial completion date: Jan 2028 --> May 2028 | Trial primary completion date: Jan 2028 --> Jun 2027
    Enrollment change • Trial completion date • Trial primary completion date
    7d
    A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults (clinicaltrials.gov)
    P1, N=60, Recruiting, University Hospital Tuebingen | Suspended --> Recruiting
    Enrollment open • First-in-human